Abstract
Current researches on treatments for metabolic diseases involve a class of biological receptors called peroxisome proliferator-activated receptors (PPARs), which control the metabolism of carbohydrates and lipids. A subclass of these receptors, PPARδ, regulates several metabolic processes, and the substances that activate them are being studied as new drug candidates for the treatment of diabetes mellitus and metabolic syndrome. In this study, several PPARδ agonists with experimental biological activity were selected for a structural and chemical study. Electronic, stereochemical, lipophilic and topological descriptors were calculated for the selected compounds using various theoretical methods, such as density functional theory (DFT). Fisher’s weight and principal components analysis (PCA) methods were employed to select the most relevant variables for this study. The partial least squares (PLS) method was used to construct the multivariate statistical model, and the best model obtained had 4 PCs, q 2 = 0.80 and r 2 = 0.90, indicating a good internal consistency. The prediction residues calculated for the compounds in the test set had low values, indicating the good predictive capability of our PLS model. The model obtained in this study is reliable and can be used to predict the biological activity of new untested compounds. Docking studies have also confirmed the importance of the molecular descriptors selected for this system.
Similar content being viewed by others
References
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diab Care 30:162–172
Day C (1998) Traditional plant treatments for diabetes mellitus: pharmaceutical foods. Brit J Nutr 80:5–6
Crawford JM, Cotran RS (2000) Robbins: Patologia Estrutural e Funcional, 6ª edn. Guanabara Koogan, RJ
Rang HP, Dale MM, Ritter JM (2001) Farmacologia, 4ª edn. Guanabara Koogan, R
Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428
McLellan KCP, Barbalho SM, Cattalini M, Lerario AC (2007) Diabetes mellitus do tipo 2, síndrome metabólica e modificação no estilo de vida. Rev Nutr 20:515–524
Lombo B, Satizábal C, Villalobos C, Tique C, Kattah W (2007) Prevalencia del síndrome metabólico en pacientes diabéticos. Acta Med Colomb 32:9–15
Gomes MB (2006) Glitazonas e síndrome metabólica: mecanismos de ação, fisiopatologia e indicações terapêuticas. Arq Bras Endocrinol Metab 50:271–280
Matos AFG, Moreira RO, Guedes EP (2003) Aspectos neuroendócrinos da síndrome metabólica. Arq Bras Endocrinol Metab 47:410–420
Azevedo AP, Papelbaum M, D'elia F (2002) Diabetes e transtornos alimentares: uma associação de alto risco. Rev Bras Psiquiatr 24:77–80
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab Care 21:1414–1431
Hogan P, Dall T, Nikolov P (2003) Economic costs of diabetes in the US in 2002. Diab Care 26:917–932
Sakata S (2007) Diabetes mellitus entre os idosos no município de São Paulo: uma visão longitudinal. Master Thesis, University of São Paulo
Alberte JSP (2004) Diabetes mellitus tipo 2: significado da doença para os pacientes e suas repercussões para a aderência ao tratamento clinico. Master Thesis, University of Campinas
Miller AR (2006) Today’s Challenges and Tomorrow’s Opportunities: Ligands to Peroxysome Proliferator-Activated Receptors as Therapies for Type 2 Diabetes and the Metabolic Syndrome. Drug Dev Res 67:574–578
Maltarollo VG, Homem-de-Mello P, Honório KM (2010) Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. J Mol Model 16:799–804
Isley WL (2003) Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2:581–586
Dixit A, Saxena AK (2008) QSAR analysis of PPAR-gamma agonists as anti-diabetic agents. Eur J Med Chem 43:73–80
Parra S, Mejía LC (2001) Implicaciones farmacológicas de los receptores activados por los proliferadores de peroxisomas (PPAR). IATREIA 14:35–46
Berger J, Moller DE (2002) The Mechanisms of Action of PPARs. Annu Rev Med 53:409–435
Carvalho I, Pupo MT, Borges ADL, Bernardes LSC (2003) Introdução a modelagem molecular de fármacos no curso experimental de química farmacêutica. Quim Nova 26:428–438
Thomas G (2003) Química Medicinal: Uma Introdução. Guanabara Koogan, RJ
Honorio KM, Da Silva ABF (2005) A study on the influence of molecular properties in the psychoactivity of cannabinoid compounds. J Mol Model 11:200–209
Nowaczyk A, Kulig K, Malawska N (2009) 1-(3-(4-Arylpiperazin-1-yl)-propyl)-Pyrrolidin-2-one Derivatives as 1-Adrenoceptor Antagonists: A QSAR Study. QSAR Comb Sci 28:979–988
Weber KC, Honorio KM, Bruni AT, Andricopulo AD, Da Silva ABF (2006) A partial least squares regression study with antioxidant flavonoid compounds. Struct Chem 17:307–313
Mehdipour AR, Safarpour MA, Taghavi F, Jamali M (2009) Density Functional Theory-based Quantitative Structure Activity Relationship (QSAR) Study of Alkanol and Alkanthiol Derivatives. QSAR Comb Sci 28:568–575
Calgarotto AK, Miotto S, Honório KM, Da Silva ABF, Marangoni S, Silva JL, Comar M, Oliveira KMT, Da Silva SL (2007) A multivariate study on flavonoid compounds scavenging the peroxynitrite free radical. J Mol Struct THEOCHEM 808:25–33
Wickens P, Zhang C, Ma X, Zhao Q, Amatruda J, Bullock W, Burns M, Cantin L, Chuang C, Claus T, Dai M, Dela Cruz F, Dickson D, Ehrgott FJ, Fan D, Heald S, Hentemann M, Iwuagwu CI, Johnson JS, Kumarasinghe E, Ladner D, Lavoie R, Liang S, Livingston JN, Lowe D, Magnuson S, Mannelly G, Mugger I, Ogutu H, Pleasic-Williams S, Schoenleber RW, Shapiro J, Shelekhin T, Sweet L, Town C, Tsutsumi M (2007) Indanylacetic acids as PPAR-δ activator insulin sensitizers. Bioorg Med Chem Lett 17:4369–4373
Gaussview 3.0 (2003) Gaussian Inc, Carnegie Office Park, Building 6, Pittsburgh, CA
Iwashita A, Mihara K, Amano Y, Orita M, Matsuoka N (to be published) PPAR-Delta Activation Contributes to Neuroprotection Against Thapsigargin-Induced SH-SY5Y Cell Death
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA , Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA (2003) Gaussian 03. Gaussian Inc, Wallingford, CT
Becke AD (1993) A new mixing of Hartree-Fock and local density-functional theories. J Chem Phys 98:1372–1377
Lee C, Yang W, Parr RG (1988) Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37:785–789
Sosa C, Andzelm J, Elkin BC, Wimmer E, Dobbs KD, Dixon D (1992) A Local Density Functional Study of the Structure and Vibrational Frequencies of Molecular Transition-Metai Compoundst. J Phys Chem 96:6630–6636
Godbout N, Slahub DR, Andzelm J, Wimmer E (1992) Optimization of Gaussian-type basis sets for local spin density functional calculations. Part I. Boron through neon, optimization technique and validation. Can J Chem 70:560–571
HyperChem: Molecular Visualization and Simulation (2000) HYPERCUBE, Ontario
Dragon 2.1 (2002) CHEMOMETRICS, Milano
Broto P, Moreau G, Vandycke C (1984) Molecular-Structures-Perception, Auto-Correlation Descriptor and SAR Studies. Eur J Med Chem 19:66–70
Okey RW, Stenselz HD (1996) A QSAR-based biodegradability model - A QSBR. Wat Res 30:2206–2214
Pirouette 3.10 (2002) INFOMETRIX, Woodinville, WA
Sybyl 8.1, Tripos International: 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA
Connors RV, Wang Z, Harrison M, Zhang A, Wanska M, Hiscock S, Fox B, Dore M, Labelle M, Sudom A, Johnstone S, Liu J, Walker NPC, Chai A, Siegler K, Li Y, Coward P (2009) Identification of a PPAR[delta] agonist with partial agonistic activity on PPAR[gamma]. Bioorg Med Chem Lett 19:3550–3554
Giaginis C, Theocharis S, Tsantili-Kakoulidoua A (2009) A QSAR Study on Indole-Based PPAR-g Agonists in Respect to Receptor Binding and Gene Transactivation Data. QSAR Comb Sci 28:802–805
Murphy GJ, Holder JC (2000) PPARg agonists: therapeutic role in diabetes, inflammation and cancer. TIPS 12:469–474
Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV (1999) Molecular Recognition of Fatty Acids by Peroxisome Proliferator–Activated Receptors. Mol Cell 3:397–403
Honorio KM, Da Silva ABF (2003) An AM1 study on the electron-donating and electron-accepting character of biomolecules. Int J Quantum Chem 95:126–132
Arroio A, Honório KM, Da Silva ABF (2010) Propriedades químico-quânticas empregadas em estudos das relações estrutura-atividade. Quim Nova 33:694–699
Acknowledgments
The authors would like to thank FAPESP (The State of São Paulo Research Foundation), CNPq (The National Council for Scientific and Technological Development) and CAPES (Coordination for the Improvement of High Education Personnel) for funding.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maltarollo, V.G., Homem-de-Mello, P. & Honorio, K.M. Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor δ. J Mol Model 17, 2549–2558 (2011). https://doi.org/10.1007/s00894-010-0935-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-010-0935-x